Contineum Therapeutics (NASDAQ:CTNM) versus Anebulo Pharmaceuticals (NASDAQ:ANEB) Critical Contrast

Contineum Therapeutics (NASDAQ:CTNM) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.

Profitability

This table compares Contineum Therapeutics and Anebulo Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-27.09%	-25.64%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

Insider and Institutional Ownership

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 7.9% of Contineum Therapeutics shares are held by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Contineum Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -1.83, suggesting that its share price is 283% less volatile than the S&P 500.

Valuation and Earnings

This table compares Contineum Therapeutics and Anebulo Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50.00 million	10.12	-$59.98 million	($1.95)	-6.94
Anebulo Pharmaceuticals	N/A	N/A	-$8.48 million	($0.19)	-1.73

Anebulo Pharmaceuticals has lower revenue, but higher earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Contineum Therapeutics and Anebulo Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1	1	3	0	2.40
Anebulo Pharmaceuticals	1	1	0	0	1.50

Contineum Therapeutics currently has a consensus price target of $20.00, suggesting a potential upside of 47.82%. Given Contineum Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Contineum Therapeutics is more favorable than Anebulo Pharmaceuticals.

Summary

Contineum Therapeutics beats Anebulo Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

About Contineum Therapeutics

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.